S&P 500 Financials Sector SEC Filings — March 30, 2026

30-03-2026

Inseego Corp. filed an S-3 shelf registration statement on March 30, 2026, registering up to 6,204,703 shares of Common Stock for potential resale by certain Registering Stockholders, including 767,165 shares newly issued in January 2026 under an Exchange Agreement, shares from a November 2024 exchange of $91.5M in 3.25% convertible notes due 2025, and up to 2,929,770 shares issuable under warrants that could yield $37.0M in proceeds if exercised. While warrant exercises could provide cash inflows, the filing notes that these shares represent a substantial portion of outstanding stock (new shares ≈4.7%), and sales or perceived sales could cause a significant decline in the public trading price of Common Stock, which closed at $11.31 on March 23, 2026.

• ·Post-effective amendment No. 1 to prior Form S-1 (File No. 333-283913, effective December 30, 2024).
• ·Company qualifies as a 'smaller reporting company' with reduced disclosure requirements.
• ·Inseego will not receive proceeds from resale of shares but will bear registration expenses (excluding selling stockholders' commissions).

30-03-2026

Tempest Therapeutics, Inc. (TPST) completed an asset acquisition on February 3, 2026, from Erigen LLC and Factor Bioscience Inc., obtaining CAR T-cell therapies TPST-2003 (Phase 1/2a in rrMM), TPST-2206, TPST-3003, and TPST-3206 in exchange for 8,268,495 shares of common stock. This S-3 shelf registration statement enables resale of those shares by selling stockholders, including Matthew Angel and Lotus Capital (BVI) Limited, with no proceeds to the company. As a smaller reporting company (non-affiliate market value < $700M, revenue < $100M), TPST notes potential for reduced disclosures, less active trading, and higher share price volatility.

• ·Asset Purchase Agreement executed November 19, 2025.
• ·Exclusive worldwide licenses (excl. Greater China, India, Turkey, Russia) to patents and know-how for TPST-2003, TPST-2206, TPST-3003, TPST-3206.
• ·Right of first negotiation for licenses in Greater China.
• ·Erigen expected to dissolve post-closing and distribute shares to Matthew Angel and Lotus Capital (BVI) Limited.
• ·Company incorporated in Delaware in April 2011.

30-03-2026

Soluna Holdings reported FY 2025 revenue of $29.7 million, down 21.8% YoY from $38.0 million primarily due to a 30.8% decline in Bitcoin hashprice and reduced Bitcoin mined (113.2 vs 274), though Q4 revenue grew 9% sequentially to $9.2 million from $8.4 million. The company raised ~$142 million in capital, increasing total cash 750% to $88.8 million and unrestricted cash to $76 million, while expanding its power pipeline to 4.3+ GW and net PP&E 58% to $74.8 million amid operational milestones like Dorothy 2 completion and Kati 1 construction. However, gross profit fell to $6.5 million (22% margin from 25%), Adjusted EBITDA turned negative at -$13.2 million from +$0.942 million, and Q4 gross profit declined sequentially to $1.8 million from $2.3 million.

• ·FY 2025 Cost of Revenue decreased $5.4M YoY to $23.3M due to HPE contract termination savings.
• ·SG&A increased $11.9M YoY driven by stock-based comp ($5.2M), people costs ($4.3M), and legal fees ($1.7M).
• ·Project Dorothy 1B cryptocurrency mining revenue: $11,406k; gross profit: $252k.
• ·Generate Credit Facility provides up to $100M scalable project-level capital.

30-03-2026

Boston Scientific Corporation (BSX) has filed an S-4/A registration statement related to its proposed merger with Penumbra, Inc. (PEN), where a wholly owned subsidiary (Pinehurst Merger Sub, Inc.) will merge with Penumbra, making it a wholly owned subsidiary of BSX, subject to Penumbra stockholder approval at a special meeting on May 6, 2026, HSR Act clearance, and other regulatory approvals. Termination fees include $525M payable by Penumbra to BSX under certain circumstances such as failure to obtain stockholder approval followed by an alternative deal, and a $900M reverse termination fee payable by BSX if regulatory conditions prevent closing despite other conditions being satisfied. Penumbra reported $1.827B in total assets and $1.428B in stockholders' equity as of December 31, 2025.

• ·Merger Agreement signed on January 14, 2026.
• ·Special Meeting for Penumbra stockholders on May 6, 2026 at 10:00 a.m. PT in Alameda, CA; requires majority of outstanding shares for Merger Proposal approval.
• ·Record Date: March 26, 2026; approximately 2.9% of shares owned by Penumbra directors and officers.
• ·Merger not subject to financing condition.

30-03-2026

Capstone Green Energy Holdings, Inc. (CGEH) announced a $112.5 million strategic investment led by Monarch Alternative Capital LP, consisting of $80 million in new senior convertible preferred stock and $15 million in common stock from Monarch, plus a $17.5 million PIPE from existing investors. $85 million of proceeds will redeem legacy preferred equity held by a Goldman Sachs affiliate, simplifying the capital structure and making Capstone Green Energy LLC a wholly owned subsidiary. Remaining funds support general working capital and growth initiatives, including AI data center expansion, with board expansion to seven members including two Monarch appointees and a path to national exchange listing.

• ·Preferred Stock convertible at $5.00 per share, 5.00% PIK dividend, senior ranking, mandatory conversion if stock trades above $15.00 for 20 of 30 days.
• ·PIPE priced at $4.50 per share.
• ·45-day lock-up for Company directors and executives.
• ·Resale registration statement to be filed within 30 days of closing.
• ·Initial listing application for national exchange within 12 months.
• ·Expected closing on or about March 31, 2026.

30-03-2026

Unicycive Therapeutics reported full year 2025 financial results with a reduced net loss attributable to common stockholders of $26.6 million ($1.67 per share) compared to $37.8 million ($5.65 per share) in 2024, driven by lower R&D expenses of $9.1 million versus $20.0 million, though G&A expenses rose to $20.4 million from $12.1 million amid commercial launch preparations. As of March 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, supporting operations into 2027. The FDA accepted the OLC NDA resubmission in January 2026, setting a PDUFA target action date of June 29, 2026.

• ·FDA accepted OLC NDA resubmission in January 2026, supported by three clinical studies, preclinical data, and CMC; no concerns on preclinical, clinical, or safety data from original NDA.
• ·OLC resubmission in December 2025 addressed drug product manufacturing by third-party vendor.
• ·UNI-494 granted orphan drug designation for prevention of Delayed Graft Function in kidney transplant patients; completed Phase 1 dose-ranging safety study.
• ·Stockholders’ equity increased to $30.2 million as of Dec 31, 2025 from $7.4 million as of Dec 31, 2024.

30-03-2026

ProCap Financial, Inc. dismissed MaloneBailey, LLP as its independent auditor and engaged BDO USA, P.C. effective March 27, 2026, with no disagreements but noting a previously disclosed material weakness in internal controls over financial reporting. At its virtual Annual Meeting on the same date, shareholders approved the Merger Proposal (33,172,356 for vs. 15,065,559 against), election of Eric Jackson as Class I director, amendment to the 2025 Equity Incentive Plan, and adjournment proposal, representing approvals amid significant opposition on the merger. The company has 83,422,775 shares of common stock outstanding as of the February 10, 2026 record date.

• ·Audit reports by MaloneBailey for period June 17, 2025 (inception) through December 31, 2025 contained no adverse opinions, qualifications, or modifications.
• ·Material weakness in internal controls: (i) inadequate segregation of duties and effective risk assessment, (ii) insufficient written policies and procedures for GAAP and SEC guidelines.
• ·Proposal No. 3 (Equity Plan Amendment): For 33,103,985; Against 13,867,806; Abstain 1,273,649.
• ·Proposal No. 4 (Adjournment): For 33,711,635; Against 10,745,407; Abstain 3,788,398.
• ·No consultations with BDO prior to engagement regarding accounting or auditing matters.

30-03-2026

Sensei Biotherapeutics reported full year 2025 financial results with R&D expenses decreasing 41% YoY to $11.0 million and G&A expenses falling 13% to $11.3 million, resulting in a narrower net loss of $21.1 million versus $30.2 million in 2024; however, cash, cash equivalents, and marketable securities declined 49% to $21.2 million from $41.3 million. The company completed its acquisition of Faeth Therapeutics, adding the lead program PIKTOR (an all-oral combination of serabelisib and sapanisertib), concurrent with a $200 million private placement expected to fund key clinical milestones including topline Phase 2 data in endometrial cancer and Phase 1b initiation in breast cancer by year-end 2026.

• ·Total operating expenses FY2025: $22.3M vs $32.6M FY2024.
• ·Long-lived asset impairment: $0 FY2025 vs $0.951M FY2024.
• ·Total other income: $1.2M FY2025 vs $2.5M FY2024.
• ·Net loss per share: $(16.72) FY2025 vs $(24.01) FY2024.
• ·Clinical milestones for PIKTOR expected by year-end 2026.
• ·PIKTOR targets PI3K/AKT/mTOR pathway for endometrial, breast, ovarian, and lung cancer.

30-03-2026

Perimeter Acquisition Corp. I (PMTRW), a blank check company with no operating history or revenues, filed its 10-K on March 30, 2026, disclosing sponsor compensation including 5,911,500 founder shares for $24,460 and 638,000 private placement units, alongside up to $1,500,000 in convertible working capital loans at $10.00 per unit that could cause significant dilution. The filing details 180-day transfer restrictions on founder shares post-IPO or business combination, uncapped reimbursement for sponsor out-of-pocket expenses, and redemption mechanics at approximately $10.00 per share in case of business combination or failure within 24 months of IPO closing. No initial business combination has been completed.

• ·Transfer restrictions on founder shares apply until 180 days after initial business combination or subsequent liquidation/merger/share exchange.
• ·Must complete initial business combination within 24 months from IPO closing or redeem public shares.
• ·No cap on reimbursement of out-of-pocket expenses for sponsor, officers, directors, or affiliates related to business combination activities.
• ·Private placement warrants are non-redeemable.

30-03-2026

Picard Medical, Inc. reported total net revenues of $4,940 thousand for the year ended December 31, 2025, up 13% YoY from $4,391 thousand, with products revenue increasing 12% to $4,746 thousand and rentals surging 42% to $194 thousand. However, gross loss widened 82% to $(204) thousand due to a 38% rise in product costs to $3,432 thousand despite a 15% decline in rental costs, while net loss grew 28% to $(27,002) thousand driven by 86% higher other expenses including derivative losses up 64% and interest expense up 76%. Operating expenses declined slightly 4% to $13,053 thousand with R&D down 10% and SG&A flat at -2%, and cash balances improved to $7,451 thousand from $96 thousand bolstered by financing activities.

• ·Auditors included explanatory paragraph on going concern due to ability to continue as a going concern.
• ·Cash used in operating activities increased to $15,673 thousand from $11,874 thousand.
• ·No cash used in investing activities in either year.
• ·Total current liabilities decreased to $18,695 thousand from $35,325 thousand.
• ·Preferred stock converted to common stock; no Series A-1 outstanding as of Dec 31 2025.
• ·Stock-based compensation expense $754 thousand in 2025.

30-03-2026

Accelerant Holdings, an emerging growth company under the JOBS Act, has issued its proxy statement for the hybrid 2026 Annual General Meeting on May 12, 2026, at 10:00 a.m. BST in London or via webcast, with pre-registration required at https://web.viewproxy.com/arx/2026. Shareholders of record as of March 13, 2026, will vote on electing three Class I directors for three-year terms expiring in 2029 and ratifying PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026. As of the record date, 222,160,004 common shares are outstanding, comprising 116,757,858 Class A shares (1 vote each) and 105,402,146 Class B shares (10 votes each), with a simple majority quorum required.

• ·Quorum requires holders of a simple majority of common shares present in person or by proxy.
• ·Proxy deadlines: mail by May 11, 2026; internet at www.AALvote.com/ARX by 11:59 p.m. ET on May 11, 2026.
• ·Election of directors requires simple majority of votes cast; ratification of PwC requires majority of votes cast at meeting with quorum.
• ·No cumulative voting in director elections; abstentions and broker non-votes do not impact proposals.

30-03-2026

ConocoPhillips' 2026 Proxy Statement highlights strong 2025 performance, including full-year production of 2,375 MBOED, $8.0 billion earnings ($6.35 EPS), $19.8 billion cash from operating activities, and $9.0 billion returned to shareholders ($5.0B buybacks, $4.0B dividends) while achieving over $1 billion in Marathon Oil integration synergies and a 15% YoY improvement in Lower 48 drilling efficiencies. The company advanced LNG strategy with 10 MTPA total offtake, met emissions targets including zero routine flaring, and identified $1 billion in additional cost savings on track for 2026. Stockholders are asked to vote on electing 13 directors, ratifying auditors, approving executive compensation advisory, and a stockholder proposal for an independent board chairman at the virtual Annual Meeting on May 12, 2026.

• ·Virtual Annual Meeting on May 12, 2026 at 9:00 a.m. CDT; record date March 18, 2026.
• ·Board recommends FOR election of 13 directors, ratification of auditors, and advisory approval of NEO compensation; AGAINST stockholder proposal for independent board chairman.
• ·Gold Standard Reporting awarded by Oil & Gas Methane Partnership 2.0 (OGMP 2.0) in 2025.
• ·First oil achieved at Surmont Pad 104W-A.

30-03-2026

Volato Group, Inc. entered into an ATM Sales Agreement with Curvature Securities, LLC to offer and sell up to $3,700,000 of Class A Common Stock at-the-market. The company provided an update on its pending merger with M2i Global, Inc., where M2i shareholders are expected to receive approximately 85% ownership of the combined company (via ~119.2M shares), resulting in significant dilution for existing Volato shareholders who will hold ~15%. The merger faces risks including stockholder approvals, integration challenges, operational disruptions, and potential failure to realize strategic benefits.

• ·ATM sales made via methods permitted under Rule 415, including directly on NYSE American LLC.
• ·Merger Agreement originally dated July 28, 2025; shelf registration on Form S-3 (File No. 333-290219) effective September 30, 2025.
• ·Company plans to seek stockholder approval for potential reverse stock split to meet NYSE American listing requirements.
• ·Merger closing subject to M2i Global and Volato stockholder approvals, with risks of delays, termination, or adverse business impacts.

30-03-2026

Baker Hughes Co's DEF 14A Proxy Statement filed March 30, 2026, discloses 5% shareholders including The Vanguard Group (121,897,643 shares, 12.29%), JPMorgan Chase & Co. (86,781,218 shares, 8.75%), BlackRock Inc. (84,558,359 shares, 8.53%), and State Street Corporation (65,170,011 shares, 6.57%), with 991,757,347 Class A Common Stock shares outstanding as of March 23, 2026. Current directors, nominees, and executive officers as a group beneficially own 1,839,049 shares (less than 1%), including vested DSUs for directors ranging from 0 to 53,880.774 as of December 31, 2025. Related party transactions include $250,000 compensation in 2025 to an immediate family member of CEO Lorenzo Simonelli and $150,000 annual compensation approved for the son of director Cynthia B. Carroll effective April 2026.

• ·Company's Insider Trading Policy prohibits directors and executive officers from derivative transactions in Company stock and pledging shares as collateral.
• ·No personal loans or extensions of credit to directors or executive officers.
• ·Governance & Corporate Responsibility Committee reviews related person transactions per Item 404 of Regulation S-K.

30-03-2026

In its inaugural FY2025, Fermi America (FRMI) raised approximately $1.8 billion in capital, including a $785 million dual-listed IPO on Nasdaq and LSE, and capitalized $935 million into property, plant, and equipment through December 31, 2025, converting funds into tangible assets like turbines, pipelines, and substations for Project Matador. Key milestones include delivery of 478 MW SGT-800 turbines, contracting 1.1 GW F-Class units financed by MUFG's $500 million loan, securing a ~6 GW Clean Air Permit, and completing initial construction on 7,570 acres with 11.3 miles of fencing, 4.6 miles of gas pipeline, and 7.2 miles of water lines. As a first-year company, no prior periods exist for comparison, reflecting all positive execution with no declines or flat metrics reported.

• ·Secured 300,000 MMBtu per day firm gas from Energy Transfer.
• ·Water supply: up to 18.5 MGD total, including 2.5 MGD from City of Amarillo and 5.5 MGD agreement expandable to 10 MGD.
• ·Power capacities: 478 MW SGT-800 (combined cycle, delivered); 1.1 GW F-Class (combined cycle, contracted); >200 MW GE 6B (combined cycle, refurbishing); grid connection 86 MW initial to 200 MW.
• ·NRC accepted COLA for four AP1000 reactors in September 2025; environmental review notice March 20, 2026.
• ·Filed additional ~5 GW Clean Air Permit application March 27, 2026.

30-03-2026

Reviva Pharmaceuticals reported a reduced net loss of $19.9 million for FY2025 ($5.48 per share) compared to $29.9 million ($17.73 per share) in FY2024, driven by lower R&D expenses ($11.7M vs. $22.9M), with cash at $14.4M at year-end and ~$23M post-March 2026 offering to fund into Q1-2027. However, G&A expenses rose slightly to $8.5M, and FDA feedback requires a second Phase 3 RECOVER-2 trial in mid-2026 before NDA for brilaroxazine in schizophrenia, despite positive 1-year OLE data showing sustained efficacy (PANSS total -18.1) and favorable safety. The company raised $29M gross via three equity offerings in 2025-2026.

• ·1-year OLE: PANSS total score improvement -18.1; positive symptoms -5.0; negative symptoms -4.4; <1% relapse.
• ·Weight gain ~1.5 kg over 52 weeks; no clinically meaningful movement disorders; favorable lipids, glucose, prolactin normalization.
• ·NDA-enabling carcinogenicity studies completed; cGMP manufacturing of drug substance and product batches done.
• ·Three new U.S. provisional patents filed; EP3749324 granted for pulmonary fibrosis.

30-03-2026

CBAK Energy reported explosive Q4 2025 consolidated net revenues of $58.80 million, up 131.8% YoY from $25.37 million, fueled by 524.2% growth in Light Electric Vehicles (LEV) to $12.92 million and 944.1% surge in Hitrans battery raw materials to $27.98 million; however, Electric Vehicles declined 91.1% to $0.06 million and Residential Energy Supply & UPS fell 10.6% to $17.84 million. Full year 2025 revenues grew 11% to $195.19 million from $176.61 million, with LEV up 252% to $36.36 million and Hitrans up 123% to $89.21 million, but Battery Business total dropped 22% due to a 45% decline in Residential Energy Supply & UPS to $68.82 million, resulting in gross margin compression to 9.4% from 23.7% and a net loss of $9.38 million versus $11.79 million net income in 2024.

• ·Q4 2025 gross profit $4.28M (margin 7.3%) vs $3.31M (13.1%) in Q4 2024.
• ·FY 2025 cost of revenues $176.77M including $6.61M inventory write-downs.
• ·Q4 2025 operating loss $8.01M vs $6.59M in Q4 2024; FY 2025 operating loss $18.44M vs $8.79M income in FY 2024.
• ·Q4 R&D expenses $5.30M (up from $3.80M); FY R&D $15.80M (up 21%).
• ·Cash increased to $75.68M as of Dec 31, 2025 from $60.79M.

30-03-2026

AIxCrypto Holdings reported total assets of $31,279,846 as of December 31, 2025, up significantly from $4,686,519 in 2024, driven by cash and cash equivalents rising to $19,332,707 and new digital assets of $10,250,497, bolstered by $40,991,044 in financing activities including $4.5 million from Series A-3 Preferred and substantial Series B Preferred issuances. However, the company posted a larger net loss attributable to shareholders of $19,528,742 in 2025 versus $6,346,795 in 2024, with total expenses increasing 129% to $13,202,096 due to higher general and administrative costs and a $4,195,000 credit loss expense, alongside a $3,588,106 net loss on digital assets. Stockholders’ equity grew to $27,950,609 from $2,679,036, but operating cash use worsened slightly to $(6,951,458).

• ·Short-term notes receivable net: $343,060 (2025) vs $2,010,692 (2024), after allowance of $4.6M (2025) vs $360,000 (2024).
• ·Related party payable: $1,648,945 (2025) vs $0 (2024).
• ·Issuance of $4,166,900 notes receivable to a publicly traded entity from Apr 2024-Dec 2025 at 18% interest.
• ·Secured Convertible Note $264,000 principal (+$44,000 OID) issued Apr 2025, repaid Jan 2026.
• ·Subscription agreement Sept 19, 2025 for $41M: issued 337,432 common shares and 17,783 Series B shares by Sept 29, 2025.

30-03-2026

Sable Offshore Corp. announced on March 30, 2026, via press release, the resumption of oil sales from the Santa Ynez Unit through the Santa Ynez Pipeline System, effective March 29, 2026. This operational milestone follows prior interruptions and supports the company's production activities. No financial impacts or quantitative metrics were disclosed.

30-03-2026

Sysco announced a definitive agreement to acquire Jetro Restaurant Depot for $21.6 billion in cash and 91.5 million Sysco shares, representing a $29.1 billion enterprise value at 14.6x Jetro's CY2025 Operating Income, expected to be immediately accretive to margins, mid-to-high single-digit EPS in year one and low-to-mid teens in year two, with $250 million in annualized cost synergies. The transaction combines Sysco's FY2025 sales of over $81 billion with Jetro's CY2025 $16 billion revenue, $2.1 billion EBITDA, and $1.9 billion free cash flow, boosting pro forma 2025 revenue ~20%, adjusted EBITDA ~45%, and free cash flow ~55%, while Jetro operates as a standalone segment. Sysco reaffirms FY2026 guidance for 3-5% sales growth and adjusted EPS at the high end of $4.50-$4.60, with Q3 USFS local volume growth over 3.0% YoY, but will pause share repurchases post-close to de-leverage after funding $21 billion with new debt.

• ·Jetro Restaurant Depot to operate as standalone business segment reporting to Kevin Hourican; no anticipated workforce reductions.
• ·Transaction expected to close by Q3 FY2027, subject to regulatory approvals.
• ·Sysco pausing share repurchase program post-close to reduce net leverage by at least 1.0x in first 24 months toward 2.75x long-term target.
• ·Jetro shareholders to own ~16% of Sysco post-close.
• ·Q3 FY2026 adjusted EPS consensus ~$0.94; full Q3 results on April 28, 2026.

30-03-2026

Greenpro Capital Corp. (GRNQ) outlines its core services in its 10-K filing, including advising on company formation in jurisdictions like Hong Kong, the US, and British Virgin Islands, corporate finance consulting, FinTech solutions such as cloud accounting and payroll systems, cross-border listing advisory, and digital asset services like cryptocurrency trading and equity crowdfunding for SMEs. The company supports client financing stages from seed to expansion to enable global business development and increased cash flows. However, it highlights substantial risks including digital asset price volatility, regulatory scrutiny, banking service restrictions, market manipulation, concentrated ownership, and potential non-compliance penalties in China that could harm operations.

• ·Filing Date: March 30, 2026
• ·Services include bank loan referrals, company secretarial services, due diligence investigations, liquidation and insolvency advice, international tax planning in China, and trust/wealth management advisory
• ·Client financing stages: Seed (assets/R&D), Start-up (product development/initial marketing), Expansion (growth/production capacity)
• ·Risks encompass blockchain partnership failures, limited digital asset acceptance by retailers/banks, lack of liquid markets, whale sales impact, system outages, cyberattacks, and China regulatory penalties like fines, injunctions, or license losses

30-03-2026

NiSource Inc.'s 2026 Proxy Statement outlines the virtual annual meeting on May 11, 2026, seeking stockholder approval to elect 12 director nominees, advisory approval of Named Executive Officer compensation (following 97% support in 2025 Say-on-Pay vote), and ratification of Deloitte & Touche LLP as independent auditors for 2026. The company, serving 3.8 million natural gas and electric customers across six states with 7,700 employees, emphasizes strong governance practices including majority voting, proxy access, separate Chair and CEO, and a Net Zero GHG emissions goal by 2040. No declines or flat metrics are reported in this governance-focused filing.

• ·Annual meeting: May 11, 2026, 10:30 a.m. Central Time, virtual via www.virtualshareholdermeeting.com/NI2026
• ·Record date: Close of business on March 16, 2026
• ·Proxy materials first sent: March 30, 2026
• ·Governance highlights: All independent directors except CEO; annual Say-on-Pay votes; no repricing of options, hedging/pledging, or single-trigger change-in-control vesting
• ·Local brands serve customers in Indiana, Ohio, Pennsylvania, Maryland, Virginia, and Kentucky

30-03-2026

Ingevity Corporation, along with Ingevity Holdings SRL and Ingevity UK Ltd, entered into a Second Amendment and Restatement Agreement dated March 26, 2026, amending their existing credit agreement to establish new Revolving Commitments totaling $750 million, with proceeds used to repay all outstanding revolving loans under the prior facility. The transaction involves JPMorgan Chase Bank, N.A. as Administrative Agent and other lenders, with effectiveness subject to standard conditions including legal opinions, solvency certificates, and repayment of prior obligations. No comparative financial metrics or performance declines are disclosed in the filing.

• ·Existing Credit Agreement originally dated June 23, 2022
• ·Amendment Arrangers: JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citizens Bank, N.A., PNC Bank, National Association, TD Securities (USA) LLC
• ·Legal opinions required from Wachtell, Lipton, Rosen & Katz, McGuireWoods LLP, Loyens & Loeff CVBA, NautaDutilh BV/SRL, Cahill Gordon & Reindel (UK) LLP
• ·Engagement Letter dated February 19, 2026

30-03-2026

Boeing Co (BA-PA) filed a DEFA14A Definitive Additional Proxy Statement on March 30, 2026. The provided content consists solely of standard boilerplate language referencing SEC filings such as Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, along with a forward-looking statements disclaimer. No specific financial data, proposals, or material updates are detailed in the excerpt.

30-03-2026

Vine Hill Capital Investment Corp. shareholders overwhelmingly approved the business combination with CoinShares International Limited at the March 27, 2026 extraordinary general meeting, with 92.6% of votes cast in favor of the Business Combination Proposal (22,095,264 For vs. 1,764,990 Against). The company notified Nasdaq on March 24, 2026, of its intent to voluntarily delist its units (VCICU), Class A ordinary shares (VCIC), and warrants (VCICW) following the merger closing, with Odysseus Holdings Limited's ordinary shares and warrants expected to list on Nasdaq thereafter. The transaction is anticipated to close on March 31, 2026, subject to customary conditions including Jersey regulatory approvals.

• ·Shareholder Meeting quorum: holders of 16,526,920 Class A and 7,333,334 Class B ordinary shares present, representing 81.342% of voting power as of record date March 2, 2026.
• ·All Shareholder Proposals approved, including SPAC Merger Proposal (identical vote to Business Combination), Organizational Document Proposals (some with 150,000 abstentions), and NTA Proposal (23,685,207 For, 25,047 Against, 150,000 Abstain).
• ·Registration Statement on Form F-4 (No. 333-293885) declared effective March 16, 2026; Proxy Statement mailed same day.
• ·Merger structure: SPAC merges into SPAC Merger Sub (Odysseus (Cayman) Limited) on March 30, 2026, followed by scheme of arrangement acquiring CoinShares on March 31, 2026.

30-03-2026

Osisko Development Corp. filed its Form 40-F Annual Report on March 30, 2026. The filing lists the company's Common Shares (no par value, trading symbol ODV) registered on the New York Stock Exchange and Warrants (exercisable for one Common Share at $10.70, trading symbol ODVWZ) on The Nasdaq Stock Market LLC.

30-03-2026

OneMedNet Corp reported total revenue of $1,359 thousand for the year ended December 31, 2025, up 111% YoY from $643 thousand, driven by a 329% surge in data delivery revenue (Real-World Data) to $1,254 thousand; however, subscription revenue (BEAM) declined sharply 70% to $105 thousand. The net loss narrowed 72% to $2,801 thousand from $10,129 thousand, benefiting from $5,569 thousand gain on troubled debt restructurings and other non-operating income, though gross margins remained negative at $(503) thousand (worsened 79% YoY) and the company faces going concern doubts amid bitcoin holdings risks. Target markets include Imaging AI, medical device companies, and pharmaceutical companies, with the Real World Evidence market projected to grow from $2.62B in 2024 to $4.55B by 2030 at 8.2% CAGR.

• ·Cost of revenue increased to $1,862 thousand (137% of revenue) from $924 thousand (144% of revenue).
• ·Company highlights risks including going concern, revenue decline reversal, IP protection, bitcoin volatility, and third-party supplier reliance.
• ·Long-term strategies focus on global reach expansion and sales network growth targeting Imaging AI, medical device, and pharmaceutical companies.

30-03-2026

Aptera Motors Corp reported a Q4 2025 GAAP net loss of $15.5 million, up from $8.9 million YoY, and full-year GAAP net loss of $43.9 million, up from $34.9 million YoY, driven by higher operating expenses of $15.1 million in Q4 and $48.1 million for the year. Adjusted non-GAAP net loss improved for the full year to $18.5 million from $20.1 million, supported by $4.2 million in other income primarily from a California Energy Commission grant, though cash and equivalents declined to $9.6 million from $13.2 million at year-end. Post-period, the company raised $17.1 million in Q1 2026 to support validation assembly and production goals.

• ·Q4 GAAP net loss per share: $(0.57) vs $(0.38) prior year
• ·FY GAAP net loss per share: $(1.79) vs $(1.52) prior year
• ·Public company transition costs: $717K in Q4 2025 and $1.1M FY 2025
• ·Stock-based compensation: $6.1M Q4 2025 ($4.5M G&A, $1.5M R&D); $24.3M FY 2025
• ·Follow-on public offering: $9.0M on Jan 26, 2026; warrant exercises $8.1M including $6.3M inducement on Mar 12, 2026
• ·Carlsbad facility lease extended through March 31, 2028

30-03-2026

Aprea Therapeutics, Inc. (Nasdaq: APRE) announced an oversubscribed $30 million private placement financing led by Soleus Capital, with participation from Vestal Point Capital, Squadron Capital Management, existing investors, and insiders, expected to close on or about March 31, 2026. The offering includes pre-funded warrants and warrants to purchase approximately 37.2 million shares of common stock each, with gross proceeds intended for general corporate purposes, R&D, and expanding the ACESOT-1051 Phase 1 trial enrollment in uterine serous carcinoma (USC) and Cyclin E-overexpressing platinum-resistant ovarian cancer (PROC) patients. The proceeds are expected to extend the company's cash runway into Q1 2028, with dose escalation completion anticipated in Q2 2027.

• ·Warrants exercisable immediately upon issuance and expire on the earlier of December 31, 2029, or 30 days after pro rata exercise of corresponding Pre-Funded Warrant
• ·Company to file SEC registration statement for resale of securities
• ·Oppenheimer & Co. Inc. acting as lead placement agent; Maxim Group LLC as co-lead

30-03-2026

On March 26, 2026, Universal Health Services, Inc.'s Compensation Committee approved 2026 annual incentive bonus formulae for executive officers under the 2022 Executive Incentive Plan, with targets at 150% of base salary for CEO Marc D. Miller and 100% for others, based on adjusted net income per diluted share and return on capital. A discretionary $1.07 million cash bonus was approved for Executive Chairman Alan B. Miller for 2025. The Committee also awarded time-based RSUs and performance-based PBRSUs to executives under the 2020 Omnibus Stock and Incentive Plan, computed at $185.09 per share.

• ·RSUs vest in four equal annual installments starting on first anniversary of March 26, 2026 grant date.
• ·PBRSUs based on three-year average (2026-2028) Adjusted EBITDA net of NCI; 50% payout at 90% threshold, 200% at 110%+ threshold.
• ·Annual incentives for Sim and Peterson: 25% corporate criteria (adjusted net income per diluted share and return on capital), 75% divisional pre-tax income net of capital cost.
• ·Corporate performance criteria exclude nonrecurring/non-operational items; divisional targets adjustable similarly.

30-03-2026

Lexeo Therapeutics reported Q4 and FY 2025 financial results, highlighting a strong cash position of $246.6 million sufficient into 2028 following a $154 million equity financing in October 2025, alongside pipeline progress including FDA alignment for LX2006's SUNRISE-FA 2 pivotal trial initiation in 1H 2026 and positive interim data for LX2006 and LX2020 programs. R&D expenses decreased 12% YoY to $16.2 million in Q4 and 14% to $63.8 million for the year, but G&A expenses increased 44% to $45.5 million annually due to leadership expansions; net loss improved 19% to $20.9 million in Q4 from $25.9 million prior year but widened slightly 2% to $100.0 million for FY 2025 versus $98.3 million in 2024.

• ·LX2006 Phase I/II data showed statistically significant mFARS score improvements vs. UNIFAI natural history control; no Grade 3+ SAEs.
• ·LX2020 high-dose cohorts: dose-dependent PKP2 protein expression increases, reduced arrhythmia burden, symptom improvements in majority; no significant complement activation.
• ·FDA approved LX2006 Sf9 manufacturing process comparability in Nov 2025.
• ·Q4 net loss per share $0.27 vs. $0.78 prior year; FY weighted average shares 53.6M vs. 31.8M.

30-03-2026

Fathom Holdings Inc. reported full year 2025 revenue of $420.5 million, up 25.4% YoY from $335.2 million, driven by 26.8% brokerage revenue growth to $399.0 million following the My Home Group acquisition and 14.6% increase in real estate transactions to 42,405. However, Q4 2025 revenue declined 1.2% to $90.6 million from $91.7 million, with brokerage down 3.2% to $84.9 million and transactions falling 14.2% to 8,501 amid market softness, though mortgage revenue surged 70.0% to $3.4 million and title 38.5% to $1.8 million. Full year net loss improved to $20.3 million from $21.6 million, with Adjusted EBITDA loss narrowing to $4.0 million from $5.7 million.

• ·Agent network declined 1.2% to 14,135 licenses at Dec 31, 2025 from 14,300.
• ·Divestiture of location technology business completed in November 2025, recognizing $0.9 million loss.
• ·Gross profit increased 6.0% to $7.1 million in Q4 2025.
• ·Cash and equivalents $5,773 thousand at Dec 31, 2025, down from $7,127 thousand.
• ·Total assets $78,044 thousand at Dec 31, 2025, up from $75,397 thousand.
• ·Withheld guidance for Q1 2026; plans to release 2026 guidance in Q2 earnings.
• ·Strategic partnerships with ByOwner and Move Concierge announced.

30-03-2026

AEON Biopharma reported full year 2025 financial results showing a net loss of $39,222 thousand versus net income of $42,005 thousand in 2024, driven by operating losses of $12,803 thousand and negative fair value changes, though R&D expenses declined 71% to $4,094 thousand and cash increased to $3,006 thousand. Positive developments include positive initial comparative analytical results for ABP-450 biosimilar (100% amino-acid sequence match to BOTOX®), constructive FDA BPD Type 2a feedback, $6 million PIPE financing with $4.2 million additional proceeds in January 2026, and over 90% reduction in outstanding debt. The company strengthened leadership with John Bencich as CFO and anticipates completing most analytical comparability work in 2026.

• ·LC/MS analysis demonstrated 93–99% sequence coverage across all five proteins in the 900 kDa botulinum toxin type A complex.
• ·Cash and cash equivalents expected sufficient to fund operations into Q3 2026 including $4.2M PIPE proceeds.
• ·Abstract accepted for poster presentation at 2026 AAN Annual Meeting (April 18-22, 2026) on primary structure comparability of ABP-450.
• ·Convertible notes at $34,600 thousand (including $34,600 thousand related party) as of Dec 31, 2025 vs $11,689 thousand in 2024.
• ·Stockholders' deficit increased to $(55,027) thousand from $(28,569) thousand.

30-03-2026

S&T Bancorp's 2026 Proxy Statement discloses 2025 non-employee director compensation totaling $70,000 to $165,833 per director, primarily from $70,000 annual cash retainers and $50,000 restricted stock units (1,290 units at $38.76/share), with prorated awards for new director Stephanie N. Doliveira ($40,833 cash + $29,167 stock) and forfeited stock for resigned Christine J. Toretti ($160,000 cash only). Ernst & Young audit fees increased 0.7% YoY to $1,313,737 while tax fees declined 12.3% to $195,660, with audit-related fees flat at $31,973. The Board revised stock ownership guidelines to 4x the annual cash retainer effective post-January 28, 2026.

• ·No political contributions or spending in fiscal 2025.
• ·Revised stock ownership guidelines require directors to own 4x annual cash retainer ($280,000) by later of five years from January 28, 2026 or five years from initial appointment.
• ·All directors satisfied prior stock ownership guidelines ($100,000/$250,000 thresholds) as of January 28, 2026.
• ·Aon plc deemed independent by Compensation Committee for 2025 consulting services.
• ·Ernst & Young ratified as independent auditors for fiscal 2026.

30-03-2026

American Eagle Outfitters reported total net revenue of $5,547,236 thousand for FY ending January 31, 2026, up 4% YoY from $5,328,652 thousand, driven by 12% growth in Aerie to $1,940,924 thousand while American Eagle grew only 1% to $3,411,237 thousand and Other declined 7%. However, gross profit fell 3% to $2,025,321 thousand with margin contracting 270 basis points to 36.5%, operating income dropped 47% to $226,222 thousand amid $101,603 thousand in impairments (vs $17,561 thousand prior), and net income attributable to AEO declined to $191,983 thousand from $329,380 thousand.

• ·Quiet Platforms impairment and restructuring charges: $58,966 thousand FY2026
• ·Corporate and store impairment and restructuring charges: $42,637 thousand FY2026
• ·Corporate restructuring costs: $10,729 thousand FY2025
• ·Hong Kong retail operations impairment and restructuring costs: $6,832 thousand FY2025
• ·Diluted EPS attributable to AEO: $1.09 FY2026 vs $1.68 FY2025
• ·Depreciation and amortization expense flat at ~$212M, down to 3.8% of revenue
• ·General corporate expenses increased to $428,783 thousand from $423,766 thousand

30-03-2026

Empire District Bondco, LLC's 10-K annual report details its directors, executive officers, and corporate governance under Item 10. The leadership includes Tim Wilson (48, Manager and President, appointed January 17, 2025), Fraser McNamee (41, Manager, Treasurer, and Secretary, appointed September 15, 2025), and Jennifer A. Schwartz (52, Independent Manager with extensive capital markets experience). No financial performance metrics or changes are highlighted in this section.

• ·Tim Wilson's prior roles: President of Central Region – Electric for Liberty Utilities Service Corp. (since July 2023), VP Electric Operations (2020-2023), VP Strategic Projects and Energy Supply (2019-2020), Central Region Director of Electric Operations – Services (2017-2019).
• ·Fraser McNamee's prior roles: VP Finance and Corporate Controller for Algonquin (since April 2023), Senior Director Accounting and Reporting (2022-2023), Director of Finance (2017-2022).
• ·Jennifer A. Schwartz: 25 years in U.S. and global capital markets, serves as independent director/manager for bankruptcy remote transactions, Delaware statutory trusts since 2004.

30-03-2026

Akari Therapeutics' total operating expenses declined 20% YoY to $17,275 thousand for the year ended December 31, 2025, from $21,643 thousand in 2024, driven by a sharp 60% drop in R&D expenses to $2,815 thousand and elimination of one-time merger-related ($3,273 thousand) and restructuring expenses ($1,723 thousand). However, G&A expenses were nearly flat, down only 4% to $9,280 thousand, and the company recorded a new $5,180 thousand impairment loss on other intangible assets, resulting in an operating loss of $17,275 thousand. The filing highlights ongoing operating losses, material weaknesses in internal controls, no initiated clinical studies, and the need for substantial additional capital amid various development and regulatory risks.

• ·Identified material weaknesses in internal control over financial reporting.
• ·No clinical studies initiated for any programs in active pipeline.
• ·Entered White Lion Ordinary Share Purchase and Registration Rights Agreements with purchase options at 97-100% of ADS prices or with 20% discount under certain conditions.
• ·Risk of Nasdaq delisting due to past and potential future non-compliance.
• ·Relies on novel, unproven ADC Platform technologies.

30-03-2026

Glucotrack reported full year 2025 net loss of $19.4 million, an improvement from $22.6 million in 2024 primarily due to prior-year non-cash losses, while cash and cash equivalents increased to $7.4 million from $5.6 million supported by a $4.0 million private placement. However, operating expenses rose to $16.1 million from $14.5 million, with R&D up slightly to $9.8 million and G&A increasing $1.2 million to $6.3 million amid ongoing pre-revenue development. The company advanced its CBGM technology with three new USPTO patents, an Australian feasibility study, and plans for FDA IDE submission in Q2 2026 targeting U.S. trials in H2 2026.

• ·Basic and diluted loss per share increased to $31.22 in 2025 from $4,106 in 2024 due to significant share dilution.
• ·Weighted average shares outstanding 621,094 in 2025 vs 5,503 in 2024.
• ·Derivative financial liabilities decreased to $1 thousand from $17,421 thousand.
• ·Stockholders’ equity improved to $2,828 thousand from ($13,000) thousand.
• ·IDE submission to FDA planned for Q2 2026; U.S. clinical trial launch targeted H2 2026.

30-03-2026

Avenue Therapeutics, Inc. (ATXI) discloses significant risks in its 10-K filing, including reliance on third parties for manufacturing product candidates, potential inadequate coverage by payors limiting revenue prospects, challenges in establishing sales and marketing capabilities, and ongoing significant losses since inception with expectations of continued losses. Potential milestone payments are noted up to $17 million for AJ201 and up to $79 million for AXS-17 (related to BAER-101) upon achieving certain commercial sales events, though these are contingent and in the context of commercialization risks and AJ201 termination.

• ·Filing date: March 30, 2026
• ·Risks include compliance with federal/state anti-kickback, false claims laws, off-label promotion restrictions, and privacy laws differing across jurisdictions

30-03-2026

On March 30, 2026, 5&2 Studios, Inc. held its annual stockholder meeting, where shareholders overwhelmingly approved a 1-for-173,750 reverse stock split of Series A and Series B Common Stock, with cash payments of $3.75 per pre-split share for fractional shares; all six director nominees were elected with over 70 million 'For' votes each; and the appointment of Tanner LLC as independent auditors for the fiscal year ending December 31, 2025, was ratified. The meeting achieved 100% quorum with 6,950,000 Series A shares (10 votes each) and 5,585,229 Series B shares (1 vote each) present or by proxy. No proposals failed, with minimal opposition across all votes.

• ·Board approved Amendment to Certificate of Incorporation on December 31, 2025
• ·Record date for Annual Meeting: March 16, 2026
• ·Proxy statement filed with SEC on March 17, 2026
• ·Director election votes: Derral Eves (For: 70,702,362; Against: 16,905; Abstain: 98,802); Dallas Jenkins (For: 70,763,016; Against: 16,550; Abstain: 38,503); Brooke Asiatico (For: 70,520,622; Against: 28,450; Abstain: 268,997); Cris Doornbos (For: 70,525,337; Against: 24,625; Abstain: 268,107); Matt Rearden (For: 70,526,762; Against: 27,570; Abstain: 265,557); David Bagheri (For: 70,527,367; Against: 22,480; Abstain: 268,222)
• ·Auditor ratification votes: For: 70,568,824; Against: 25,255; Abstain: 223,990
• ·Reverse Stock Split approval votes: For: 70,547,379; Against: 233,565; Abstain: 37,125
• ·Adjournment proposal approved (votes not detailed beyond approval)

30-03-2026

Fidelity BancShares (N.C.), Inc. and Fidelity Bank announced a definitive all-cash merger agreement to acquire 100% of Affinity Bancshares, Inc. (NASDAQ: AFBI) for approximately $142.8 million, or $23.00 per share subject to adjustments. The transaction will combine the entities into an organization with $5.5 billion in total assets, $4.6 billion in total deposits, and $3.6 billion in loans, marking Fidelity's entry into Georgia with two additional branches. The deal has unanimous board approval and is expected to close in Q3 2026, subject to regulatory and stockholder approvals.

• ·Affinity Bank founded in 1928, formerly Newton Federal Bank.
• ·Fidelity Bank founded in 1909.
• ·Financial advisors: Raymond James & Associates, Inc. (Fidelity), Performance Trust Capital Partners, LLC (Affinity).
• ·Legal advisors: Ward and Smith, P.A. (Fidelity), Luse Gorman, PC (Affinity).
• ·Proxy statement for special stockholder meeting to be distributed; available on SEC site and Affinity IR site.

30-03-2026

Pliant Therapeutics, Inc. entered into a 2026 Sales Agreement with Leerink Partners LLC for an at-the-market offering program to sell shares of common stock with an aggregate offering price of up to $50.0 million. Effective March 27, 2026, the company terminated its prior 2021 Sales Agreement with Cantor Fitzgerald & Co., under which no shares had been sold and no termination penalties apply.

• ·Termination of 2021 Sales Agreement effective March 27, 2026
• ·No shares sold under 2021 Sales Agreement prior to termination
• ·No termination penalties for 2021 Sales Agreement
• ·2021 Sales Agreement filed as Exhibit 1.2 to Form S-3ASR (File No. 333-257684) on July 2, 2021

30-03-2026

Myseum, Inc. reported net revenues of $550 for FY 2025, up 26% YoY from $436, but operating expenses surged 71% to $5.49M, driving a larger loss from continuing operations of $(5.25M) versus $(2.95M) in 2024. A $2.88M gain on sale from discontinued operations resulted in a net loss attributable to shareholders of $(2.61M), improved from $(4.24M) prior year, with total assets growing 34% to $7.20M while cash declined slightly to $0.75M and Myseum stockholders' equity fell 11% to $6.10M.

• ·Equity compensation plans approved by security holders: 691,820 securities outstanding at weighted average exercise price $23.94; 308,180 available for future issuance.
• ·Basic and diluted EPS from continuing operations: $(1.25) FY2025 vs $(1.00) FY2024; net loss EPS: $(0.62) vs $(1.43).
• ·Accounts payable and accrued expenses increased to $873,691 from $603,378.

30-03-2026

Ensysce Biosciences reported Q4 and FY 2025 financial results, with clinical milestones including first patient enrollment in the PF614-301 Phase 3 trial for post-surgical pain and positive FDA feedback supporting the development pathway for PF614-MPAR under Breakthrough Therapy designation. Cash and cash equivalents increased to $4.3 million as of December 31, 2025, from $3.5 million in 2024, while federal grant funding was slightly down FY to $5.1 million from $5.2 million. However, net loss widened to $10.2 million for FY 2025 from $8.0 million in 2024, driven by R&D expenses rising 44% to $10.4 million due to expanded clinical and preclinical programs.

• ·U.S. Patent allowed in December 2025 covering MPAR® technology through 2042.
• ·European Patent Office Notice of Allowance in December 2025 for PF8026.
• ·Cash used in operating activities $7.8M in FY 2025 vs $7.5M in 2024.
• ·G&A expenses flat at $1.1M in Q4 and up slightly to $4.9M FY.
• ·Clinical sites for PF614-301 include CenExel JBR in Salt Lake City, Utah, and CenExcel Atlanta.

30-03-2026

United Acquisition Corp. I, a Cayman Islands SPAC with no operating history or revenues, filed its 10-K for the period from inception (October 22, 2025) through December 31, 2025, ahead of its initial public offering completed on January 30, 2026. The company must complete an initial business combination within a 24-month completion window but faces significant risks including failure to identify a suitable target, high redemptions by public shareholders, and external factors like geopolitical events and inflation. Permitted withdrawals from trust account interest are limited to the lesser of $500,000 or 5% of annual interest for working capital and taxes.

• ·Company inception: October 22, 2025
• ·Financial statements period: October 22, 2025 (inception) through December 31, 2025
• ·IPO completion date: January 30, 2026
• ·Completion window: 24 months from IPO closing
• ·Sponsor: United Acquisition SPAC LLC (Delaware limited liability company affiliated with executive officers and directors)
• ·Underwriters: Lucid Capital Markets, LLC and Chardan Capital Markets, LLC
• ·Ordinary shares par value: $0.0001
• ·Special resolution threshold: at least two-thirds (2/3) majority

30-03-2026

Socket Mobile, Inc. reported FY2025 revenues of $15,078,332, down 19.6% YoY from $18,762,520, with gross profit declining 20.8% to $7,488,330 amid lower sales volumes. Operating expenses decreased 10.1% to $10,706,862, but operating loss widened to $3,218,532 from $2,462,501, and net loss surged to $14,378,538 from $2,242,350 due to a $10,663,419 tax expense versus a $551,000 benefit. Total assets fell sharply to $14,437,340 from $27,345,781, driven by the elimination of deferred tax assets, while stockholders' equity dropped to $4,278,613 from $18,160,495.

• ·Inventories net decreased to $4,220,822 from $4,941,500, with raw materials down to $5,006,124 but reserves up to $1,135,942.
• ·Net cash used in operating activities increased to $1,249,819 from $521,485.
• ·Proceeds from subordinated convertible notes payable totaled $1,250,000, and related party $250,000 in FY2025.
• ·Deferred tax assets reduced to $0 from $10,663,419.
• ·Q4 2025 revenue $3,963K down from Q4 2024 $4,831K; quarterly revenues trended lower overall in 2025.
• ·Basic net loss per share $(1.81) vs $(0.30) YoY.
• ·Cash paid for interest $488,851 up from $366,491.

30-03-2026

Liberty Energy Inc. (NYSE: LBRT) announced a proposed private offering of $450.0 million aggregate principal amount of convertible senior notes due 2032, with an option for initial purchasers to buy up to an additional $50.0 million. Proceeds will fund capped call transactions to mitigate dilution upon conversion and general corporate purposes. The offering includes potential market impacts from hedging activities by counterparties, which could affect the Class A Common Stock price positively or negatively.

• ·Notes mature on March 1, 2032; interest payable semiannually starting September 1, 2026
• ·Conversion possible under certain conditions prior to December 1, 2031, thereafter at any time until maturity
• ·Liberty may redeem notes for cash on or after March 1, 2029, if stock price >=130% of conversion price
• ·Offering to qualified institutional buyers under Rule 144A; not registered under Securities Act

30-03-2026

OnKure Therapeutics entered into a securities purchase agreement on March 27, 2026, for a private placement expected to generate approximately $150.0 million in gross proceeds through the sale of 26,713,636 shares of Class A common stock at $4.15 per share and pre-funded warrants to purchase 9,430,959 shares at $4.1499 per underlying share, with closing anticipated on March 31, 2026. The company elected Dr. Liam Ratcliffe, affiliated with lead investor AI Biotechnology LLC, as a Class I director effective upon closing, and plans to use proceeds for preclinical/clinical development of next-generation PI3Kα inhibitors OKI-345 and OKI-355, with IND submissions targeted for H1 2027. However, despite progress in the PIKture-01 trial (completed dose escalations with n=38 single-agent and n=33 + fulvestrant), the company will not pursue further independent clinical development of OKI-219.

• ·Private Placement closing subject to customary conditions on March 31, 2026.
• ·180-day lock-up for executives/directors and Company on share issuances post-Closing.
• ·Registration Statement to be filed within 30 days after Closing, with effectiveness targets of 90-120 days.
• ·Pre-Funded Warrants exercisable at $0.0001 per share, no expiration until fully exercised.
• ·Phase 2 dose evaluation in PIKture-01 (OKI-219 triplets) to complete in 2026; mature data presentation by year-end.
• ·Dr. Ratcliffe to receive standard non-employee director compensation per Company policy.